

# Systematic review and meta-analysis of outcomes after revisional bariatric surgery following a failed adjustable gastric band

Sharples, Alistair J.; Charalampakis, Vasileios; Daskalakis, Markos; Tahrani, Abd; Singhal, Rishi

DOI:

[10.1007/s11695-017-2677-7](https://doi.org/10.1007/s11695-017-2677-7)

License:

Other (please specify with Rights Statement)

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Sharples, AJ, Charalampakis, V, Daskalakis, M, Tahrani, A & Singhal, R 2017, 'Systematic review and meta-analysis of outcomes after revisional bariatric surgery following a failed adjustable gastric band', *Obesity surgery*. <https://doi.org/10.1007/s11695-017-2677-7>

[Link to publication on Research at Birmingham portal](#)

**Publisher Rights Statement:**

The final publication is available at Springer via <http://dx.doi.org/10.1007/s11695-017-2677-7>

**General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

**Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

**Title: Systematic review and meta-analysis of outcomes after revisional bariatric surgery following a failed adjustable gastric band.**

**Shortened Title:** Revisional bariatric surgery

**Manuscript Type:** Original research

**Authors:**

1. Alistair J Sharples MBChB MSc FRCS, [Department of upper GI surgery](#), Heart of England NHS [Foundation](#) Trust, [Birmingham, UK](#). [alsharples@yahoo.co.uk](mailto:alsharples@yahoo.co.uk)
2. Vasileios Charalampakis, [Department of upper GI surgery](#), Heart of England NHS [Foundation](#) Trust, [Birmingham, UK](#). [vcharalambakis@gmail.com](mailto:vcharalambakis@gmail.com)
3. Markos Daskalakis, [Department of upper GI surgery](#), Heart of England NHS [Foundation](#) Trust, [Birmingham, UK](#). [marcosdaskalakis@yahoo.gr](mailto:marcosdaskalakis@yahoo.gr)
4. Abd [A](#) Tahrani\*, [Department of Diabetes and Endocrinology](#), Heart of England NHS [Foundation](#) Trust, [Birmingham, UK](#), [Institute of Metabolic and Systems Research, University of Birmingham, Birmingham, UK](#), [Centre of Endocrinology Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK](#).  
[abd.tahrani@nhs.net](mailto:abd.tahrani@nhs.net).
5. Rishi Singhal\*, [Department of upper GI surgery](#), Heart of England NHS [Foundation](#) Trust. [rishi.singhal@heartofengland.nhs.uk](mailto:rishi.singhal@heartofengland.nhs.uk)

**\*AAT and RS contributes equally as joint senior authors**

**Correspondence to:**

Alistair Sharples

Upper GI and Bariatric Department, Heartlands Hospital, Birmingham, B9 5SS.

[alsharples@yahoo.co.uk](mailto:alsharples@yahoo.co.uk)

**Conflict of interest statement:**

The authors (Mr A Sharples, Mr V Charalampakis, Mr M Daskalakis, Dr A Tahrani and Mr R Singhal) all confirm that they have no conflict of interests to declare.

Dr A [A](#) Tahrani is a clinician scientist supported by the National Institute for Health Research (NIHR) in the UK. The views expressed in this publication are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health.

**Title:** Systematic review and meta-analysis of outcomes after revisional bariatric surgery following a failed adjustable gastric band.

**Shortened Title:** Revisional bariatric surgery

**Manuscript Type:** Original research

## **Abstract**

**Introduction:** Laparoscopic adjustable gastric band (LAGB) related complications have been reported in significant numbers of patients often leading to band removal. Increasingly revisional bariatric surgery (RBS) is offered, most commonly either band to roux-en-y gastric bypass (B-RYGB) or band to sleeve gastrectomy (B-SG).

**Objectives:** We conducted a systematic review and meta-analysis of studies to evaluate the efficacy of RBS following failed LAGB.

**Methods** Medline, Embase, The Cochrane Library and NHS Evidence were searched for English language studies assessing patients who had undergone LAGB and who subsequently underwent RBS (either B-RYGB or B-SG).

**Results:** Thirty-six studies met the inclusion criteria. In total there were 2617 patients. B-RYGB was performed in 60.5% (n=1583). There was only one death within 30 days reported (0.0004%). The overall pooled morbidity rate was 13.2%. There was no difference between the B-RYGB and B-SG groups in overall morbidity, leak rate or return to theatre. Percentage excess weight loss (%EWL) following the revisional procedure for all patients combined at 6, 12 and 24 months was 44.5%, 55.7% and 59.7% respectively. There was no statistical difference in %EWL between B-RYGB and B-SG at any time point. The rates of remission of diabetes, hypertension and obstructive sleep apnoea were 46.5%, 35.9% and 80.8% respectively.

**Conclusions:** Randomised controlled trials (RCTs) do not exist on this issue but the available observational evidence does suggest that RBS is associated with generally good outcomes similar to those experienced after primary surgery. Further, high quality research, particularly RCTs, is required to assess long-term weight loss, comorbidity and quality of life outcomes.

## Introduction

The prevalence of obesity worldwide continues to grow and is a significant burden on individuals and healthcare systems. Bariatric surgery is the most effective treatment option that results in significant long term sustainable weight loss.{{593 Colquitt,J.L. 2014; 595 Courcoulas,A.P. 2014; 594 Gloy,V.L. 2013}} The laparoscopic adjustable gastric band (LAGB) was the first bariatric procedure to gain widespread acceptance due to its good weight loss results in the short term, its relative simplicity and low early complication rates.{{599 Chapman,A.E. 2004}} However, randomised and non-randomised studies have shown that roux-en-y gastric bypass (RYGB) and sleeve gastrectomy (SG) are superior to LAGB in terms of weight loss and impact on obesity related comorbidities.{{601 Boza,C. 2011; 605 Hutter,M.M. 2011; 600 Tice,J.A. 2008}} As a result there has been a significant fall worldwide in the number of LAGBs performed in favour of RYGB and SG.{{597 Buchwald,H. 2013; 596 Buchwald,H. 2009; 598 Angrisani,L. 2015}}

The rate of LAGB related complications such as band erosion, band slippage, oesophageal dilatation and dysmotility and tube or port dysfunction can be as high as 15-58% often leading to band removal.{{602 Gustavsson,S. 2002; 607 Lanthaler,M. 2010; 603 Suter,M. 2006; 604 Spivak,H. 2012; 584 Weber,M. 2003}} In addition, a substantial proportion of patients fail to lose sufficient weight with LAGB alone;{{606 Biertho,L. 2005; 607 Lanthaler,M. 2010}} in one study insufficient weight loss (defined as percentage excess weight loss (%EWL) of <25%) was reported in 10.5% of patients at 5 years.{{603 Suter,M. 2006}}

Increasingly therefore, revisional bariatric surgery (RBS) is being performed to remove the gastric band and convert to another bariatric procedure, most commonly RYGB or SG.

Previous systematic reviews have demonstrated both the safety and efficacy of RBS.{{609

Mahawar,K.K. 2015; 610 Cheung,D. 2014; 608 Elnahas,A. 2013}} Despite this, the efficacy of RBS in terms of weight loss might be inferior to primary bariatric surgery (PBS) and the complication rates higher.{{611 Zhang,L. 2015; 609 Mahawar,K.K. 2015; 612 Mor,A. 2013}} However, the choice that patients and clinicians face is not between RBS and PBS but between RBS and medical management in patients who have already undergone LAGB. Patients requiring RBS are different to those undergoing PBS; they have by definition failed a primary bariatric surgical intervention for a variety of reasons which might put them at higher risk for a further revisional procedure. Therefore direct comparison of RBS with PBS is not necessarily of great relevance.

In addition, while the impact of PBS on obesity-related comorbidities is well established, the impact of RBS on these comorbidities is far less certain{{499 Aftab,H. 2014; 500

Kanoupakis,E. 2001; 501 Sarkhosh,K. 2013; 498 Sovik,T.T. 2011; 497 Sjostrom,L. 2004}}

Obesity has a negative impact upon quality of life (QOL){{627 Kushner,R.F. 2000}} and there is increasing evidence that QOL can be improved significantly following bariatric surgery.{{623 Driscoll,S. 2016; 624 Major,P. 2015; 625 Andersen,J.R. 2015; 626 Hachem,A. 2016}} It is tempting to extrapolate the positive impact that PBS has been shown to have on QOL and hypothesise that RBS, if achieving similar levels of weight loss and comorbidity improvement should result in similar QOL improvements. However, patients undergoing RBS are likely to have different characteristics to patients receiving bariatric surgery for the first time. It is possible that some of those physical, psychological or social factors have contributed to the failure of their initial LAGB and therefore may be more resistant to treatment. Indeed, there is much evidence to suggest that psychological and social factors, both preoperative and postoperatively, are predictive of poorer outcomes following bariatric surgery.{{556 Gordon,P.C. 2014; 561 Kalarchian,M.A. 2008; 552 Livhits,M. 2012; 553 van Hout,G.C. 2005; 554 Wedin,S. 2014; 555 Wimmelmann,C.L. 2014}}

Hence, we aimed to conduct a systematic review and meta-analysis of observational and interventional studies to evaluate the efficacy and safety of revisional bariatric surgery (RYGB and SG) following a failed LAGB in regards to complication rates, weight loss, resolution of obesity-related comorbidities and QOL.



## **Methods**

A systematic review and meta-analysis was performed. This was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) recommendations.{{239 Moher,D. 2010}}

## **Eligibility Criteria**

English language, prospective and retrospective, observational and interventional studies were included. Studies were included if they: 1. Included patients who had undergone PBS in the form of a gastric band and who subsequently underwent RBS: either a gastric band converted to RYGB (B-RYGB) or a gastric band converted to SG (B-SG); 2. Presented data on one or more of the following postoperatively: weight change at a minimum of six months; obesity-related comorbidities at any time point; or quality of life data at any time point; 3. Included more than 10 patients. Studies including patients undergoing other types of revisional procedure (eg. revisions of vertical banded gastroplasty, revisions of sleeve gastrectomy or gastric band revisions not in the form of either B-RYGB or B-SG) were excluded unless the data regarding B-RYGB and B-SG was clearly separable from other data. Other exclusions included studies reporting on data from less than 10 patients and studies reporting data from open revisional procedures.

## **Information sources and search strategy**

A literature search was performed using Medline, Embase, The Cochrane Library and NHS Evidence up to November 2015. The search was performed using combinations of keywords: laparoscopic adjustable gastric banding; laparoscopic sleeve gastrectomy; laparoscopic roux-en-y gastric bypass; revision; revisional; reoperation; salvage; rescue; repeat; weight loss;

postoperative complication; surgical complication; morbidity; mortality; quality of life; comorbidities. The exact search strategy can be seen in Appendix 1. In addition to the above databases, the reference lists of included studies were also searched manually for additional studies.

### **Study selection**

Studies identified by the search strategy above were screened for inclusion using a two-step process. Firstly, the titles and abstracts of each study were assessed (AS and VC), if these were felt to be relevant then the full text or the paper was accessed. Secondly, the full text was assessed for the inclusion and exclusion criteria listed above (AS and VC). Differences between the assessors were resolved by discussion and mutual agreement.

### **Data collection**

Data collected included: study design; the inclusion and exclusion criteria of each study; sample size; demographic data; pre and postoperative body mass index (BMI) and/or weight; length of hospital stay (LOS); operative time; postoperative morbidity and mortality; length of follow-up; %EWL; comorbidity resolution or improvement; QOL data.

Where %EWL was not explicitly stated, this was, where possible, calculated using the formula:  $\text{postoperative weight loss} / (\text{preoperative weight-ideal body weight})$ . The weight at which a BMI of 25 would be obtained was used as the ideal body weight.{{652 Deitel,M. 2007}}

### **Summary measures and synthesis of results**

Stats Direct version 3.0.141 (StatsDirect Ltd., Altrincham, UK) was used to analyse data. Mean values for follow-up, operation time and LOS were combined and expressed using weighted means. Meta-analysis of effect size, Forest plots, relative risk and pooled

prevalence data were calculated using the DerSimonian-Laird random effects model.{{240 DerSimonian,R. 1986}} A p-value of less than 0.05 was considered statistically significant. Heterogeneity was expressed using  $I^2$ , where values of 25%, 50%, and 75% correspond to cut off points for low, moderate, and high degrees of heterogeneity.{{633 Higgins,J.P. 2003}}

## Results

### Study selection

The literature search produced 358 results. Figure 1 shows the PRISMA flow diagram detailing the process of study selection. Ultimately the process produced 36 studies which were included in the final analysis. {{416 Aarts,E. 2014; 587 Abu-Gazala,S. 2012; 463 Acholonu,E. 2009; 438 Alqahtani,A.R. 2013}} {{420 Carandina,S. 2014; 417 Carr,W.R. 2015; 430 Delko,T. 2014; 419 Emous,M. 2015}} {{464 Frezza,E.E. 2009; 447 Goitein,D. 2011; 418 Gonzalez-Heredia,R. 2015; 443 Hii,M.W. 2012}} {{451 Jacobs,M. 2011; 437 Jennings,N.A. 2013; 440 Kafri,N. 2013; 436 Khoursheed,M. 2013}} {{537 Langer,F.B. 2008; 433 Liu,K.H. 2013; 427 Marin-Perez,P. 2014; 585 Mognol,P. 2004; 435 Moon,R.C. 2013}} {{586 Moore,R. 2009; 474 Muller,M.K. 2008; 421 Noel,P. 2014; 434 Perathoner,A. 2013}} {{588 Rebibo,L. 2012; 446 Robert,M. 2011}} {{428 Silecchia,G. 2014; 441 Slegtenhorst,B.R. 2013; 475 Spivak,H. 2007}} {{465 Topart,P. 2009; 472 Topart,P. 2007; 432 Tran,T.T. 2013; 584 Weber,M. 2003}} {{439 Yazbek,T. 2013; 411 Yeung,L. 2015}}

### Study characteristics

Table 1 describes the study designs and population characteristics of the included studies.

Out of 36 studies, eight studies {{587 Abu-Gazala,S. 2012; 417 Carr,W.R. 2015; 435 Moon,R.C. 2013; 427 Marin-Perez,P. 2014; 420 Carandina,S. 2014; 411 Yeung,L. 2015; 436 Khoursheed,M. 2013; 418 Gonzalez-Heredia,R. 2015}} reported patients undergoing B-RYGB and B-SG separately. In total therefore there were 44 data sets. The 36 studies included a total sample of 2617 patients (2144 female, 415 male, two studies did not state {{418 Gonzalez-Heredia,R. 2015; 474 Muller,M.K. 2008}}). The smallest study included 10 patients (as per the inclusion criteria) {{464 Frezza,E.E. 2009}} whilst the largest

included 300 patients.{{421 Noel,P. 2014}} Twenty-six studies were retrospective and 10 were prospective studies. No controlled or randomised studies were identified. The earliest study was published in 2003,{{584 Weber,M. 2003}} while 61.0% (22 out of 36) were published in the last five years.

Most revisional procedures were B-RYGB (n=1583, 60.5%) while the remaining were B-SG (n=1034, 39.5%). Women made up 83.8% (2144 of 2559) of the overall study population and the weighted mean age was 42.7. Further demographic data can be seen in Table 2.

A one-stage procedure involves removal of the gastric band concomitantly with performance of RBS whereas with a two-stage procedure the band is removed and RBS performed at a subsequent date. In ten studies all patients underwent a one-stage conversion and in three studies all patients underwent a two-stage conversion. Nineteen studies included patients undergoing a mixture of one and two-stage procedures. Four studies did not specify whether the procedures were one or two-stage. In the 32 studies where this data was available 79.7% (1117 of 1402) of RYGBs and 47.2% (412 of 873) of SGs were performed as one-stage procedures (p<0.0001).

Twenty-eight ~~28~~ studies (2300 patients) reported their indications for revision (Table 3). The most common indication for revision was insufficient weight loss. Most studies defined this as %EWL less than 25%, however a number of studies did not provide a definition.

Twenty-four studies reported their mean length of follow-up. Weighted mean follow-up was 27.1 +/-10.0 months.

## **Synthesis of results**

### **Mortality and Morbidity**

Thirty-four studies reported on mortality and only one death within 30 days was reported (0.0004%). Morbidity and postoperative complications were reported by 33 studies. The overall pooled incidence of complications was 13.2% (95% CI: 9.5-17.3%,  $I^2=87.1\%$ , 32 studies). Seventeen studies broke complications down into early (less than 30 days) and late (greater than 30 days). The pooled early incidence of complications was 8.9% (95% CI: 6.5-11.7%,  $I^2=56.6\%$ ) and the pooled late incidence of complications was 8.1% (95% CI: 4.4-12.8%,  $I^2=85.5\%$ ). Anastomotic or staple line leak was reported in 2.0% (95% CI: 1.5-2.7%,  $I^2=13.2\%$ , 33 studies) and return to theatre in 5.4% (95% CI: 3.4-7.8%,  $I^2=73.7\%$ , 24 studies). The conversion rate to an open procedure was 1.2% (95% CI: 0.7-1.9%,  $I^2=31.1\%$ ).

Results for separate pooled analysis of studies reporting RYGB and SG can be found in table 6.

A number of studies compared morbidity between groups undergoing B-RYGB and B-SG. Meta-analysis of these studies demonstrates that there was no difference between the groups in overall morbidity (RR 1.69, 95%CI: 0.95-3.01,  $p=0.07$ , 6 studies{{436 Khoursheed,M. 2013; 427 Marin-Perez,P. 2014; 411 Yeung,L. 2015; 587 Abu-Gazala,S. 2012; 420 Carandina,S. 2014; 418 Gonzalez-Heredia,R. 2015}}), leak rate (RR 1.43, 95% CI: 0.46-4.46,  $p=0.54$ , 7 studies{{418 Gonzalez-Heredia,R. 2015; 436 Khoursheed,M. 2013; 587 Abu-Gazala,S. 2012; 420 Carandina,S. 2014; 417 Carr,W.R. 2015; 411 Yeung,L. 2015; 427 Marin-Perez,P. 2014}}) or return to theatre (RR 2.79, 95% CI: 0.80-9.80,  $p=0.11$ , 4 studies{{587 Abu-Gazala,S. 2012; 417 Carr,W.R. 2015; 436 Khoursheed,M. 2013; 411 Yeung,L. 2015}}).

None of the studies directly compared morbidity rates between one and two-stage RBS.

Pooling of the morbidity from the studies that did not mix one and two-stage procedures suggests overall morbidity for RYGB was 10.0% (95% CI: 5.7-15.2%,  $I^2=26.8\%$ , 4 studies)

and 16.2% (1 studies) in the one and two-stage groups respectively. For SG the overall morbidity was 7.3% (95% CI: 3.2-12.9%,  $I^2=60.3\%$ , 6 studies) and 6.6% (95% CI: 0.5-19.1%,  $I^2=89.9\%$ , 3 studies) in the one and two-stage groups respectively.

### **Operation Time**

Twenty-six studies reported mean operative time. The weighted mean operative time was higher for B-RYGB than B-SG (152.8 +/-41.0 minutes vs 125.0 +/-16.1 minutes,  $p<0.01$ ).

### **Length of stay**

Twenty studies reported mean LOS. The weighted mean LOS was longer for B-RYGB patients than B-SG (5.2 +/-1.9 days vs 4.1 +/-1.5 days,  $p<0.01$ ).

### **Weight loss**

Weight loss outcomes for all studies can be found in Table 7. Different studies used different weight loss outcome measures. The majority of studies (30 of 36) reported %EWL with various lengths of follow-up. %EWL for all patients combined at 6, 12 and 24 months was 44.5% (95% CI: 41.0-48.0%), 55.7% (95% CI: 52.7-58.7%) and 59.7% (95% CI: 55.6-63.8%) respectively (Table 8). Tables 9 and 10 show the %EWL following B-RYGB and B-SG. A number of studies directly compared %EWL between patients undergoing B-RYGB and those undergoing B-SG. There was no statistical difference in %EWL between these two groups of patients at 6 months (3 studies { {420 Carandina,S. 2014; 418 Gonzalez-Heredia,R. 2015; 436 Khoursheed,M. 2013} }:  $d=-0.17$ ,  $p=0.67$ ), 12 months (7 studies { {436 Khoursheed,M. 2013; 427 Marin-Perez,P. 2014; 435 Moon,R.C. 2013; 587 Abu-Gazala,S. 2012; 420 Carandina,S. 2014; 417 Carr,W.R. 2015; 418 Gonzalez-Heredia,R. 2015} }):  $d=0.11$ ,  $p=0.63$ ) and 24 months (4 studies { {420 Carandina,S. 2014; 417 Carr,W.R. 2015; 427 Marin-Perez,P. 2014; 435 Moon,R.C. 2013} }):  $d=0.37$ ,  $p=0.24$ ) (Figure 2).

A number of studies analysed the mean reduction in BMI. Weighted mean BMI decrease at 6, 12 and 24 months was 10.9 +/-2.5 (five studies{{584 Weber,M. 2003; 475 Spivak,H. 2007; 585 Mognol,P. 2004; 437 Jennings,N.A. 2013; 463 Acholonu,E. 2009}}), 11.2 +/-3.1 (five studies{{437 Jennings,N.A. 2013; 585 Mognol,P. 2004; 584 Weber,M. 2003; 441 Slegtenhorst,B.R. 2013; 430 Delko,T. 2014}}) and 11.5 +/-5.3 (three studies{{430 Delko,T. 2014; 437 Jennings,N.A. 2013; 446 Robert,M. 2011}}) respectively.

Eleven studies compared BMI before LAGB as well as before and after RBS. The mean BMI prior to LAGB in these studies was 46.4 (95% CI: 45.5-47.4), prior to RBS was 43.7 (95% CI: 42.4-44.9) and a mean of 17.2 (95% CI: 12.6-21.8) months after RBS was 33.5 (95% CI: 32.5-34.5). Therefore RBS contributed 78.8% (95% CI: 70.5-87.1%) of their total weight loss.

### **Comorbidity Outcomes**

Definitions of what exactly constituted remission or improvement of a comorbidity varied between studies. For diabetes and hypertension, all studies defined remission as the cessation of medications and improvement as the reduction in dose or number of medications. However, whereas Moon et al{{435 Moon,R.C. 2013}} required patients to achieve a fasting glucose level of <125mg/dl or a blood pressure of <140/90mmHg for diabetes and hypertension respectively, other studies did not specify this. Robert et al{{446 Robert,M. 2011}} simply required a normal HbA1C or blood pressure to be reached with no definition of what values they consider normal. The other studies{{441 Slegtenhorst,B.R. 2013; 439 Yazbek,T. 2013; 411 Yeung,L. 2015}} classified patients purely on the basis of their medications. Robert et al{{446 Robert,M. 2011}} considered obstructive sleep apnea (OSA) to be in remission if patients achieved an apnea-hypopnea index (AHI) of <15. They



considered improvement to be an AHI <30. Yazbek et al{{439 Yazbek,T. 2013}} classified remission as a cessation of the use of continuous positive airway pressure (CPAP).

Comorbidity outcomes for individual studies can be seen in Table 11. Five studies reported remission rates in patients with diabetes prior to their revisional procedure.{{411 Yeung,L. 2015; 441 Slegtenhorst,B.R. 2013; 446 Robert,M. 2011; 435 Moon,R.C. 2013; 439 Yazbek,T. 2013}} The pooled remission rate was 46.5% (95% CI: 21.2-72.9%,  $I^2=83.5$ ) among the 79 (pooled incidence of diabetes in these five studies was 19.9%, 95% CI: 14.9-25.6%) patients with diabetes studied. Three studies reported that 84.0% (95% CI: 51.5-99.7%,  $I^2=84.7$ ) of 52 (pooled incidence of diabetes = 21.4%, 95% CI: 13.0-31.1%) patients achieved either remission or improvement.{{411 Yeung,L. 2015; 435 Moon,R.C. 2013; 446 Robert,M. 2011}}

Of five studies, looking at 150 (pooled incidence of hypertension = 37.2%, 95% CI: 30.9-43.9%) patients with hypertension, four reported on remission{{439 Yazbek,T. 2013; 411 Yeung,L. 2015; 441 Slegtenhorst,B.R. 2013; 435 Moon,R.C. 2013}}. Of these, 35.9% (95% CI: 23.1-49.8%,  $I^2=57.8$ ) were considered to be in remission following revisional surgery. Three studies reported on remission or improvement and reported 71.6% (95% CI: 54.5-86.0%,  $I^2=67.6$ ) of patients achieved either remission or an improvement in their hypertension.{{435 Moon,R.C. 2013; 446 Robert,M. 2011; 411 Yeung,L. 2015}}

Only two studies reported improvement of OSA, demonstrating that 80.8% (95% CI: 65.0-92.6%,  $I^2=0.0$ ) of patients improved or were cured.{{439 Yazbek,T. 2013; 446 Robert,M. 2011}}

### **Quality of life**

Only two studies looked at QOL outcomes.{{446 Robert,M. 2011; 440 Kafri,N. 2013}} Kafri et al{{440 Kafri,N. 2013}} reported the extent to which patients agreed with four statements. They did not use a validated QOL measure. The study demonstrated that 73% of patients reported being happier, 63% reported feeling more attractive and 70% reported being satisfied with their appearance after their revisional surgery. However, only 22% were satisfied with the extent of their weight loss. Robert et al{{446 Robert,M. 2011}} used the BAROS questionnaire{{566 Oria,H.E. 1998}} to assess QOL. They reported a mean 1.5 point gain in QOL following revisional surgery.

## Discussion

Revisional bariatric surgery is on the rise due to the rapid increase in patients undergoing bariatric surgery. Unfortunately, there is a relative lack of evidence to support the practice. Unlike PBS, for which there are now well conducted longitudinal and randomised controlled trials (RCTs), our systematic review shows that the evidence for RBS is limited with no RCTs and many retrospective studies.{{616 Buchwald,H. 2004; 619 Christou,N.V. 2004; 593 Colquitt,J.L. 2014; 617 Picot,J. 2009; 620 Sjostrom,L. 2007}}

The results of this systematic review suggest that both B-RYGB and B-SG are viable options for patients after failed LAGB. The pooled morbidity and mortality rates described in this systematic review are comparable to those reported for PBS and do not suggest that RBS is associated with a significant increase in morbidity rates.{{609 Mahawar,K.K. 2015}}

Anastomotic or staple line leaks are the most feared complication following RBS. However the pooled leak rate of 2.2% after B-SG is similar to that described by Aurora et al in their systematic review of leak rates after primary SG.{{643 Aurora,A.R. 2012}} Similarly, a leak rate of 1.8% after B-RYGB is similar to that reported for primary RYGB.{{609 Mahawar,K.K. 2015; 644 Morales,M.P. 2011}} Some authors have suggested that complication rates, particularly leak rates, may be higher after B-SG than after B-RYGB.{{463 Acholonu,E. 2009; 629 Coblijn,U.K. 2013}} However, this has not been seen in our results.

Our data suggests that surgeons are more hesitant about performing one-stage B-SG than B-RYGB. B-RYGB was significantly more likely to be performed in a single stage than B-SG in our analysis. This is potentially influenced by the fear of increased leak rates in B-SG as discussed above. The limited data we are able to present would suggest that one-stage procedures are not associated with higher morbidity.

Overall, these findings suggest that patients should expect a %EWL of 44.5%, 55.7% and 59.7% at 6, 12 and 24 months respectively. A number of systematic reviews analysing weight loss after PBS have reported %EWL of 61-70%.{{616 Buchwald,H. 2004; 621 Chang,S.H. 2014; 622 Garb,J. 2009}} However, such direct comparisons lack relevance due to the differences in the study populations. Nonetheless, the %EWL observed in this systematic review is clinically relevant and would have a significant impact on obesity related comorbidities.{{637 Magkos,F. 2016; 638 Wing,R.R. 2011}} It should be emphasised again that the choice facing patients and clinicians is not between PBS and RBS but between RBS and medical management. There does not appear to be a difference in %EWL outcomes between B-RYGB and B-SG but the number of studies is small and further research to assess which procedure is most effective is needed.

This systematic review shows that there is a paucity of evidence regarding the impact of RBS on obesity related comorbidities. A small number of studies showed that a significant proportion of patients will notice an improvement in their diabetes, hypertension and OSA (84.0%, 71.6% and 80.8% respectively), which is similar to that reported following PBS.{{616 Buchwald,H. 2004; 621 Chang,S.H. 2014}} Although these results are promising, further studies are needed to assess and quantify the benefits that patients are able to achieve in their medical comorbidities following RBS.

Our study identified only two studies which looked at QOL outcomes following RBS. Of these only one{{446 Robert,M. 2011}} used a validated QOL assessment tool (the BAROS questionnaire). Their results did suggest an improvement in QOL after revisional surgery. It is important that QOL is assessed more rigorously in future studies.

Although the number of LAGB procedures performed is falling, large numbers of patients are living with a gastric band and more are being inserted each year.{{598 Angrisani,L. 2015;

597 Buchwald,H. 2013; 596 Buchwald,H. 2009}} Estimates suggest that 15-40% of patients will require revisional surgery after LAGB.{{601 Boza,C. 2011; 620 Sjostrom,L. 2007; 640 Van Nieuwenhove,Y. 2011; 641 Himpens,J. 2011; 642 O'Brien,P.E. 2013}} Therefore it is likely that the number of patients with gastric bands presenting for consideration of RBS is likely to rise further over the next decade. It is critical therefore that high quality evidence to guide practice is available and although interest in this area is growing (as evidenced by the increased number of recent studies in this review), good quality evidence is still lacking. RBS is undoubtedly more technically challenging than PBS and therefore should be performed with caution, ideally in high volume tertiary centres.{{630 Stefanidis,D. 2013}} Although our results suggest that RBS can be associated with good outcomes, selection of patients for RBS after LAGB should still be carefully considered and take into account individual patient factors, preferences and reasons for failure of LAGB.

This is not the first systematic review to focus on revisional surgery after LAGB. In 2013, Coblijn et al{{629 Coblijn,U.K. 2013}} systematically reviewed the data for B-RYGB or B-SG after primary LAGB. They concentrated on postoperative morbidity rather than longer term weight loss and concluded that although revisional surgery was safe it did carry a higher complication rate than primary procedures. Elnahas et al{{608 Elnahas,A. 2013}} in 2012 reviewed the weight loss data for patients having RBS after primary LAGB. This study predates the majority of studies included in our review and the number of patients included was much smaller. The mean %EWL they describe is similar to our findings for B-RYGB, however they describe a %EWL of only 22% for B-SG. In contrast, our findings do not suggest a difference, at least in the short term, in %EWL between B-RYGB and B-SG. Most recently, Mahawar et al{{609 Mahawar,K.K. 2015}} performed a systematic review comparing revisional RYGB and SG to their respective primary procedures. Whilst they did not restrict themselves purely to revisions following LAGB, the majority of patients had

undergone LAGB as their primary procedure. They concluded that RBS carried a higher complication rate than PBS. Although they did not perform meta-analysis on the weight loss data, they found that the majority of included studies reported inferior weight loss for RBS than PBS. Our study, is more recent and therefore includes significantly more patients. In addition, none of the previous systematic reviews include data on comorbidity resolution and QOL in the analysis.

Our study has several limitations. The quality of any systematic review is limited by the quality of the included studies. None of the included studies were RCTs, all were observational studies of variable size, design and quality. Length of follow-up, outcome measures, surgical techniques and inclusion criteria all varied widely between studies.

Although the overall number of patients was relatively large (2617), the wide variety of outcome measures analysed by the different studies means that for each outcome the number of patients available for analysis was often small. The relatively recent enthusiasm for RBS naturally limits the availability of long-term follow up and most of the studies include only relatively short term results.

## **Conclusions**

This study shows that the evidence for RBS, though limited and lacking in RCTs, suggests that RBS results in significant weight loss, obesity-related comorbidity resolution and has a positive impact on QOL, with an acceptable safety profile. Further, high quality studies, particularly RCTs are required to assess long-term efficacy and safety of RBS.

## Tables

Table 1 – Design and population characteristics of included studies

|                                      | Year | Country     | Setting       | Design        | Revisional procedure | Number | Exclusions         | % Female | Age  | Preoperative BMI | Follow up (months) |
|--------------------------------------|------|-------------|---------------|---------------|----------------------|--------|--------------------|----------|------|------------------|--------------------|
| Weber{{584 Weber,M. 2003}}           | 2003 | Switzerland | Single-centre | Prospective   | RYGB                 | 32     |                    | 71.9     | 46.0 | 42.0             | 10.5               |
| Mogno{{585 Mogno,P. 2004}}           | 2004 | France      | Single-centre | Retrospective | RYGB                 | 70     |                    | 72.5     | 41.0 | 44.9             | 7.3                |
| Muller{{474 Muller,M.K. 2008}}       | 2007 | Switzerland | Single-centre | Prospective   | RYGB                 | 30     |                    |          |      | 41.9             |                    |
| Spivak{{475 Spivak,H. 2007}}         | 2007 | USA         | Single-centre | Prospective   | RYGB                 | 33     |                    | 90.9     | 43.8 | 42.8             | 15.7               |
| Topart{{472 Topart,P. 2007}}         | 2007 | France      | Single-centre | Retrospective | RYGB                 | 32     |                    | 90.6     | 40.9 | 43.1             |                    |
| Langer{{537 Langer,F.B. 2008}}       | 2008 | Austria     | Single-centre | Retrospective | RYGB                 | 25     | Band complications | 96.0     | 38.0 | 47.6             |                    |
| Acholonu{{463 Acholonu,E. 2009}}     | 2009 | USA         | Single-centre | Retrospective | SG                   | 15     |                    | 80.0     | 46.6 | 38.7             | 6.0                |
| Frezza{{464 Frezza,E.E. 2009}}       | 2009 | USA         | Single-centre | Retrospective | SG                   | 10     |                    | 60.0     | 50*  |                  | 19.0               |
| Moore{{586 Moore,R. 2009}}           | 2009 | USA         | Single-centre | Retrospective | RYGB                 | 26     |                    | 88.5     | 46.0 | 40.0             | 18.0               |
| Topart{{465 Topart,P. 2009}}         | 2009 | France      | Single-centre | Retrospective | RYGB                 | 58     |                    | 91.4     | 42.5 | 43.2             |                    |
| Goitein{{447 Goitein,D. 2011}}       | 2011 | Israel      | Single-centre | Retrospective | SG                   | 46     |                    | 73.9     | 40   | 43.1             | 17.0               |
| Abu-Gazala{{587 Abu-Gazala,S. 2012}} | 2012 | Israel      | Single-centre | Retrospective | RYGB                 | 18     |                    | 55.6     | 43.7 | 41.6             | 14.6               |
|                                      |      |             |               |               | SG                   | 18     |                    | 77.8     | 38.6 | 40               | 14.0               |
| Jacobs{{451 Jacobs,M. 2011}}         | 2011 | USA         | Single-centre | Retrospective | SG                   | 32     |                    | 78.1     | 45.4 | 42.7             | 26.0               |
| Robert{{446 Robert,M. 2011}}         | 2011 | France      | Multi-centre  | Retrospective | RYGB                 | 85     |                    | 84.7     | 39.3 | 42.9             | 22.0               |
| Hii{{443 Hii,M.W. 2012}}             | 2012 | Australia   | Single-centre | Prospective   | RYGB                 | 82     |                    | 85.4     | 49*  | 43.0             |                    |
| Kafri{{440 Kafri,N. 2013}}           | 2013 | Israel      | Single-centre | Prospective   | SG                   | 12     |                    | 100      | 48.8 | 37.9             | 17.0               |
| Rebibo{{588 Rebibo,L. 2012}}         | 2012 | France      | Single-centre | Retrospective | SG                   | 46     |                    | 93.5     | 42.0 | 44.0             |                    |

|  |      |                 |                   |               |         |     |   |      |      |       |      |
|--|------|-----------------|-------------------|---------------|---------|-----|---|------|------|-------|------|
| <b>Alqahtani</b> {{438<br><b>Alqahtani,A.R.</b><br><b>2013}}</b>                       | 2013 | Saudi<br>Arabia | Single-<br>centre | Retrospective | SG      | 56  |   | 71.4 | 33.5 | 44.4  | 24.0 |
| <b>Jennings</b> {{437<br><b>Jennings,N.A.</b><br><b>2013}}</b>                         | 2013 | UK              | Single-<br>centre | Prospective   | RYGB    | 55  |   | 81.8 | 46.3 | 49.7  | 24.0 |
| <b>Khourshead</b> {{436<br><b>Khoursheed,M.</b><br><b>2013}}</b>                       | 2013 | Kuwait          | Single-<br>centre | Retrospective | SG      | 42  |   | 85.7 | 35.6 | 38.5* | 9.8  |
|  |      |                 |                   |               | RYGB    | 53  |   | 86.8 | 39.0 | 43.2* | 29.3 |
| <b>Liu</b> {{433<br><b>Liu,K.H. 2013}}</b>   | 2013 | France          | Single-<br>centre | Retrospective | RYGB/SG | 88  |   | 84.1 | 42.8 | 44.7  | 35.6 |
| <b>Moon</b> {{435<br><b>Moon,R.C.</b><br><b>2013}}</b>                                 | 2013 | USA             | Single-<br>centre | Retrospective | RYGB    | 41  |   | 90.2 | 43.7 | 41.8  |      |
|  |      |                 |                   |               | SG      | 13  |   | 92.3 | 40.8 | 39.0  |      |
| <b>Perathoner</b> {{434<br><b>Perathoner,A.</b><br><b>2013}}</b>                       | 2013 | Australia       | Single-<br>centre | Retrospective | RYGB    | 108 |   | 85.2 | 46*  | 37.9* | 40.8 |
| <b>Slegtenhorst</b> {{441<br><b>Slegtenhorst,B.R.</b><br><b>2013}}</b>                 | 2013 | Netherlands     | Single-<br>centre | Retrospective | RYGB    | 66  |   | 87.9 | 42.0 | 46.2  | 12.0 |
| <b>Tran</b> {{432<br><b>Tran,T.T. 2013}}</b>   | 2013 | USA             | Single-<br>centre | Retrospective | RYGB/SG | 61  |   | 91.8 | 43.7 | 42.9  | 12.4 |
| <b>Yazbek</b> {{439<br><b>Yazbek,T. 2013}}</b>   | 2013 | Canada          | Single-<br>centre | Retrospective | SG      | 90  |   | 85.6 | 41.0 | 42.0  | 24.0 |
| <b>Aarts</b> {{416<br><b>Aarts,E. 2014}}</b>   | 2014 | Netherlands     | Single-<br>centre | Retrospective | RYGB    | 195 | Band complications<br>Band in place less<br>than 1 year | 82.1 | 43.0 | 41.0  | 40.0 |
| <b>Carandina</b> {{420<br><b>Carandina,S.</b><br><b>2014}}</b>                         | 2014 | France          | Single-<br>centre | Retrospective | RYGB    | 74  |   | 93.2 | 42.1 | 45.6  | 29.1 |
|  |      |                 |                   |               | SG      | 34  |   | 91.2 | 42.4 | 47.5  | 24.2 |
| <b>Delko</b> {{430<br><b>Delko,T. 2014}}</b>   | 2014 | Switzerland     | Single-<br>centre | Prospective   | RYGB    | 48  |   | 75.0 | 43.5 | 41.9  |      |
| <b>Gonzalez-<br/>Heredia</b> {{418<br><b>Gonzalez-<br/>Heredia,R.</b><br><b>2015}}</b> | 2015 | USA             | Single-<br>centre | Retrospective | SG      | 26  |   |      | 38.6 | 48.6  |      |
|  |      |                 |                   |               | RYGB    | 12  |   |      | 33.9 | 44.6  |      |
| <b>Marin-<br/>Perez</b> {{427<br><b>Marin-Perez,P.</b><br><b>2014}}</b>                | 2014 | USA             | Single-<br>centre | Prospective   | RYGB    | 39  |   | 84.6 | 49.0 | 42.0  | 22.0 |



|                                    |      |             |               |               |      |     |  |      |       |       |      |
|------------------------------------|------|-------------|---------------|---------------|------|-----|--|------|-------|-------|------|
|                                    |      |             |               |               | SG   | 20  |  | 75.0 | 44.0  | 39.0  | 33.0 |
| Noel{{421 Noel,P. 2014}}           | 2014 | France      | Single-centre | Retrospective | SG   | 300 |  | 87.0 | 43.3  | 43.0  | 35.0 |
| Silecchia{{428 Silecchia,G. 2014}} | 2014 | Italy       | Multi-centre  | Retrospective | SG   | 76  |  | 78.9 | 45.5* | 43.9* |      |
| Carr{{417 Carr,W.R. 2015}}         | 2015 | UK          | Single-centre | Prospective   | RYGB | 64  |  | 79.7 | 47.7  | 49.5  |      |
|                                    |      |             |               |               | SG   | 25  |  | 68.0 | 49.8  | 52.7  |      |
| Emous{{419 Emous,M. 2015}}         | 2015 | Netherlands | Single-centre | Prospective   | RYGB | 257 |  | 82.9 | 43*   |       | 29.0 |
| Yeung{{411 Yeung,L. 2015}}         | 2015 | USA         | Single-centre | Retrospective | RYGB | 32  |  | 81.3 | 51.0  | 41.4  |      |
|                                    |      |             |               |               | SG   | 72  |  | 84.7 | 45.0  | 39.6  |      |

Where cells are empty data was not available

Table 2 – Basic population demographics of patients included in the systematic review

|                                  | Data sets | Patients | Number of patients (%) |
|----------------------------------|-----------|----------|------------------------|
| <b>Male</b>                      | 41        | 2559     | 415 (16.2)             |
| <b>Female</b>                    | 41        | 2559     | 2144 (83.8)            |
| <b>RYGB</b>                      | 44        | 2617     | 1583 (60.5)            |
| <b>SG</b>                        | 44        | 2617     | 1034 (39.5)            |
| <b>Age</b>                       | 38        | 2054     | 42.7 (41.6-43.7)       |
| <b>Time to revision (months)</b> | 28        | 1457     | 49.7 (42.4-57.1)       |
| <b>BMI (before LAGB)</b>         | 19        | 982      | 46.5 (45.7-47.4)       |
| <b>BMI (before revision)</b>     | 38        | 2071     | 43.4 (42.5-44.3)       |
| <b>One stage</b>                 | 29        | 2034     | 1223 (60.1)            |
| <b>Two stage</b>                 | 29        | 2034     | 811 (39.9)             |
| <b>Diabetes</b>                  | 14        | 742      | 142 (19.1)             |
| <b>Hypertension</b>              | 13        | 694      | 210 (30.3)             |
| <b>Obstructive sleep apnoea</b>  | 8         | 479      | 80 (16.7)              |
| <b>Dyslipaemia</b>               | 6         | 371      | 77 (20.8)              |

Table 3 – Indications for revisional procedure

| Indication                        | Number (%)  |
|-----------------------------------|-------------|
| Weight regain                     | 251 (10.9)  |
| Insufficient weight loss          | 1079 (46.9) |
| Slippage                          | 265 (11.5)  |
| Erosion                           | 36 (1.6)    |
| Pouch/oesophageal dilatation      | 255 (11.1)  |
| Band intolerance/dysphagia/reflux | 329 (14.3)  |
| Infection                         | 18 (0.8)    |
| Tubing complications              | 42 (1.8)    |
| Other                             | 25 (1.1)    |

Table 4 – Operative times, length of stay and postoperative morbidity described in included studies

|  | Number | Revisional procedure | One stage | Two stage | Mean Op time (mins) | LOS days Mean | LOS median | Mortality | Morbidity                     | Leak | Return to theatre             |
|--|--------|----------------------|-----------|-----------|---------------------|---------------|------------|-----------|-------------------------------|------|-------------------------------|
| Weber <sup>{584}</sup><br>Weber,M.<br>2003}}     | 32     | RYGB                 |           |           | 215                 | 8.9           |            | 0         | 4 Early<br>2 Late             | 1    | 2 Early<br>2 Late             |
| Mognol <sup>{585}</sup><br>Mognol,P.<br>2004}}   | 70     | RYGB                 | 47        | 23        |                     | 7.2           |            | 0         | 10 Early<br>6 Late            | 0    | 4 Early<br>0 Late             |
| Muller <sup>{474}</sup><br>Muller,M.K<br>.2008}} | 30     | RYGB                 |           |           |                     |               |            | 0         | Early not described<br>2 Late | 0    | Early not described<br>6 Late |
| Spivak <sup>{475}</sup><br>Spivak,H.<br>2007}}   | 33     | RYGB                 | 33        | 0         | 105                 | 2.8           |            | 0         | 1 Early<br>1 Late             | 0    | 1 Early<br>1 Late             |
| Topart <sup>{47}</sup>                           | 32     | RYGB                 | 31        | 1         | 135                 |               |            | 0         | 4                             | 0    | 3                             |

|   |    |      |    |    |     |     |     |   |                                  |   |                                  |
|---|----|------|----|----|-----|-----|-----|---|----------------------------------|---|----------------------------------|
| 2 Topart,P.<br>2007}}                               |    |      |    |    |     |     |     |   |                                  |   |                                  |
| Langer{{53<br>7<br>Langer,F.B.<br>2008}}            | 25 | RYGB |    |    | 219 | 5   |     | 0 | 1 Early<br>3 Late                | 0 |                                  |
| Acholonu{{<br>463<br>Acholonu,E.<br>2009}}          | 15 | SG   | 13 | 2  | 120 | 5.5 |     | 0 | 2 Early<br>Late not<br>described | 1 | 1                                |
| Frezza{{464<br>Frezza,E.E.<br>2009}}                | 10 | SG   |    |    | 87  |     |     | 0 | 0                                | 0 | 0                                |
| Moore{{586<br>Moore,R.<br>2009}}                    | 26 | RYGB | 24 | 2  | 160 | 3   |     | 0 | 2                                | 1 | 1                                |
| Topart{{46<br>5 Topart,P.<br>2009}}                 | 58 | RYGB | 50 | 8  | 128 | 7.7 |     | 0 | 5                                | 0 | 3                                |
| Goitein{{44<br>7 Goitein,D.<br>2011}}               | 46 | SG   | 26 | 20 | 117 | 3   |     | 0 | 3 Early<br>Late not<br>described | 2 | 2 Early<br>Late not<br>described |
| Abu-<br>Gazala{{58<br>7 Abu-<br>Gazala,S.<br>2012}} | 18 | RYGB |    |    | 195 | 3.9 |     | 0 | 1                                | 0 | 0                                |
|   | 18 | SG   |    |    | 111 | 4.3 |     | 0 | 2                                | 1 | 1                                |
| Jacobs{{451<br>Jacobs,M.<br>2011}}                  | 32 | SG   | 32 | 0  |     |     |     | 0 | 0                                | 0 | 0                                |
| Robert{{44<br>6 Robert,M.<br>2011}}                 | 85 | RYGB | 71 | 14 | 166 | 5.2 | 4   | 0 | 6 Early<br>4 Late                | 0 | 2 Early<br>1 Late                |
| Hii{{443<br>Hii,M.W.<br>2012}}                      | 82 | RYGB | 64 | 18 | 132 |     | 4.5 | 0 | 38                               | 1 | 10                               |
| Kafri{{440<br>Kafri,N.<br>2013}}                    | 12 | SG   | 12 | 0  |     |     |     | 0 |                                  |   |                                  |
| Rebibo{{58<br>8 Rebibo,L.<br>2012}}                 | 46 | SG   |    |    | 138 | 5.8 |     | 0 | 4                                | 2 | 3                                |
| Alqahtani{{<br>438<br>Alqahtani,A<br>.R. 2013}}     | 56 | SG   |    |    | 129 | 2.6 |     | 0 | 2 Early<br>O Late                | 0 | 0                                |

|  |     |         |     |    |     |     |   |   |                     |   |                    |
|--|-----|---------|-----|----|-----|-----|---|---|---------------------|---|--------------------|
| Jennings{{437<br>Jennings,N.<br>A. 2013}}                      | 55  | RYGB    | 43  | 12 |     |     | 3 |   |                     |   |                    |
| Khoursheed<br>{{436<br>Khoursheed<br>,M. 2013}}                | 42  | SG      |     |    | 108 |     | 2 | 0 | 3                   | 0 | 0                  |
|  | 53  | RYGB    |     |    | 161 |     | 3 | 0 | 11                  | 1 | 2                  |
| Liu{{433<br>Liu,K.H.<br>2013}}                                 | 88  | RYGB/SG | 29  | 59 |     |     |   | 0 | 1 Early<br>10 Late  | 1 |                    |
| Moon{{435<br>Moon,R.C.<br>2013}}                               | 41  | RYGB    | 41  | 0  | 72  | 1.2 |   |   |                     |   |                    |
|  | 13  | SG      | 10  | 3  | 90  | 1.5 |   |   |                     |   |                    |
| Perathoner{{434<br>Perathoner,<br>A. 2013}}                    | 108 | RYGB    | 56  | 52 | 197 |     | 7 | 0 | 11 Early<br>38 Late | 3 | 9 Early<br>18 Late |
| Slegtenhors<br>t{{441<br>Slegtenhors<br>t,B.R.<br>2013}}       | 66  | RYGB    | 40  | 26 |     | 4.9 |   | 0 | 10                  | 0 |                    |
| Tran{{432<br>Tran,T.T.<br>2013}}                               | 61  | RYGB/SG | 46  | 15 | 159 | 2   |   | 1 | 11 Early<br>12 Late | 4 | 3 Early<br>6 Late  |
| Yazbek{{439<br>Yazbek,T.<br>2013}}                             | 90  | SG      |     |    | 112 | 4.2 |   | 0 | 13                  | 5 |                    |
| Aarts{{416<br>Aarts,E.<br>2014}}                               | 195 | RYGB    | 195 | 0  | 112 | 4.5 |   | 0 | 14                  | 2 | 8                  |
| Carandina{{420<br>Carandina,<br>S. 2014}}                      | 74  | RYGB    | 0   | 74 | 172 | 7.1 |   | 0 | 10 Early<br>2 Late  | 4 |                    |
|  | 34  | SG      | 0   | 34 | 91  | 6.7 |   | 0 | 1 Early             | 1 |                    |
| Delko{{430<br>Delko,T.<br>2014}}                               | 48  | RYGB    | 47  | 1  | 201 |     |   | 0 | 9 Early<br>11 Late  | 2 |                    |
| Gonzalez-<br>Heredia{{418<br>Gonzalez-<br>Heredia,R.<br>2015}} | 26  | SG      | 21  | 5  | 130 | 3   |   | 0 | 0                   | 0 |                    |
|  | 12  | RYGB    | 11  | 1  |     | 2.6 |   | 0 | 0                   | 0 |                    |

|  |     |      |     |     |     |   |  |   |                    |   |                   |
|--|-----|------|-----|-----|-----|---|--|---|--------------------|---|-------------------|
|  |     |      |     |     |     |   |  |   |                    |   |                   |
| Marin-Perez{{427<br>Marin-Perez,P.<br>2014}} | 39  | RYGB |     |     | 142 | 5 |  | 0 | 1 Early<br>8 Late  | 0 |                   |
|  | 20  | SG   |     |     | 121 | 4 |  | 0 | 3 Early<br>1 Late  | 1 |                   |
| Noel{{421<br>Noel,P.<br>2014}}               | 300 | SG   | 0   | 300 | 130 |   |  | 0 | 6                  | 3 | 4                 |
| Silecchia{{428<br>Silecchia,G.<br>2014}}     | 76  | SG   | 0   | 76  |     |   |  | 0 | 13                 | 0 | 0                 |
| Carr{{417<br>Carr,W.R.<br>2015}}             | 64  | RYGB | 51  | 13  |     |   |  | 0 |                    | 1 | 1                 |
|  | 25  | SG   | 10  | 15  |     |   |  | 0 |                    | 0 | 0                 |
| Emous{{419<br>Emous,M.<br>2015}}             | 257 | RYGB | 220 | 37  |     |   |  | 0 | 12 Early<br>9 Late | 7 |                   |
| Yeung{{411<br>Yeung,L.<br>2015}}             | 32  | RYGB |     |     | 224 |   |  | 0 | 5 Early<br>0 Late  | 2 | 4 Early<br>0 Late |
|  | 72  | SG   |     |     | 156 |   |  | 0 | 4 Early<br>4 Late  | 1 | 2 Early<br>0 Late |

Table 6 – Pooled analysis of morbidity rates for RYGB and SG

|                          | <b>RYGB (%)</b>               | <b>SG (%)</b>               |
|--------------------------|-------------------------------|-----------------------------|
| <b>Overall morbidity</b> | 16.5 (11.2-22.6) $I^2 = 87.7$ | 7.7 (4.4-11.6) $I^2 = 70.9$ |
| <b>Leak rate</b>         | 1.8 (1.2-2.6) $I^2 = 4.6$     | 2.2 (1.2-3.5) $I^2 = 18.7$  |
| <b>Return to theatre</b> | 7.8 (4.9-11.3) $I^2 = 69.2$   | 2.0 (1.0-3.4) $I^2 = 19.6$  |





|  |     |      |      |      |  |      |  |  |  |  |  |      |      |
|--|-----|------|------|------|--|------|--|--|--|--|--|------|------|
| 2014}}                                   |     |      |      |      |  |      |  |  |  |  |  |      |      |
| Silecchia{{428<br>Silecchia,G.<br>2014}} | 76  | SG   | 46.5 | 66.4 |  | 78.5 |  |  |  |  |  |      |      |
| Carr{{417<br>Carr,W.R. 2015}}            | 64  | RYGB |      | 52.1 |  | 47.9 |  |  |  |  |  |      |      |
|  | 25  | SG   |      | 44.1 |  | 42.0 |  |  |  |  |  |      |      |
| Emous{{419<br>Emous,M. 2015}}            | 257 | RYGB |      |      |  |      |  |  |  |  |  | 53.0 | 67.0 |
| Yeung{{411<br>Yeung,L. 2015}}            | 32  | RYGB | 50.2 | 51.2 |  |      |  |  |  |  |  |      |      |
|  | 72  | SG   | 30.6 | 34.9 |  |      |  |  |  |  |  |      |      |

Table 8 – Pooled %EWL for RYGB and SG

|                  | <b>Studies</b> | <b>Patients</b> | <b>%EWL (95% CI)</b> |
|------------------|----------------|-----------------|----------------------|
| <b>3 months</b>  | 6              | 407             | 31.0 (28.0-34.0)     |
| <b>6 months</b>  | 16             | 1055            | 44.5 (41.0-48.0)     |
| <b>12 months</b> | 26             | 2085            | 55.7 (52.7-58.7)     |
| <b>18 months</b> | 5              | 264             | 59.1 (44.5-73.8)     |
| <b>24 months</b> | 17             | 1485            | 60.5 (56.0-65.0)     |
| <b>36 months</b> | 7              | 690             | 58.1 (48.5-67.7)     |
| <b>48 months</b> | 3              | 393             | 59.9 (52.1-67.7)     |
| <b>60 months</b> | 3              | 603             | 60.6 (31.8-89.4)     |

Table 9 - Pooled %EWL for RYGB

|                  | <b>Studies</b> | <b>Patients</b> | <b>EWL</b>       |
|------------------|----------------|-----------------|------------------|
| <b>3 months</b>  | 3              | 160             | 28.5 (23.3-33.7) |
| <b>6 months</b>  | 8              | 403             | 45.9 (42.2-49.6) |
| <b>12 months</b> | 18             | 1072            | 54.2 (50.7-57.7) |



|                  |   |     |                    |
|------------------|---|-----|--------------------|
| <b>18 months</b> | 2 | 152 | 61.5 (-41.1-164.1) |
| <b>24 months</b> | 8 | 598 | 59.5 (52.6-66.4)   |
| <b>36 months</b> | 4 | 459 | 60.7 (39.5-81.9)   |
| <b>48 months</b> | 2 | 269 | 62.0 (20.6-103.4)  |
| <b>60 months</b> | 2 | 303 | 51.3 (22.7-79.9)   |

Table 10 - Pooled %EWL for SG

|                  | <b>Studies</b> | <b>Patients</b> | <b>EWL</b>         |
|------------------|----------------|-----------------|--------------------|
| <b>3 months</b>  | 2              | 98              | 31.3 (20.0-42.6)   |
| <b>6 months</b>  | 10             | 503             | 43.1 (36.2-50.0)   |
| <b>12 months</b> | 14             | 864             | 57.6 (51.4-63.7)   |
| <b>18 months</b> | 2              | 102             | 59.6 (-11.3-130.4) |
| <b>24 months</b> | 11             | 738             | 61.8 (54.0-69.6)   |
| <b>36 months</b> | 3              | 170             | 55.4 (37.3-73.4)   |
| <b>48 months</b> | 2              | 124             | 55.4 (28.2-82.6)   |

Table 11 – Comorbidity response rates described in included studies

| Study   | Number | Procedure | Patients | Follow up (mths) | Diabetes  |           |                          | Hypertension |           |                          | OSA       |                          |
|---|--------|-----------|----------|------------------|-----------|-----------|--------------------------|--------------|-----------|--------------------------|-----------|--------------------------|
|   |        |           |          |                  | Incidence | Remission | Improvement or remission | Incidence    | Remission | Improvement or remission | Incidence | Improvement or remission |
| Robert <sup>{44}</sup><br>6 Robert, M.<br>2011}}                      | 85     | RYGB      | 85       | 22               | 26        | 22        | 26                       | 29           |           | 17                       | 12        | 10                       |
| Moon <sup>{435}</sup><br>Moon, R.C.<br>2013}}                         | 54     | RYGB/SG   | 54       |                  | 9         | 2         | 5                        | 20           | 8         | 6                        |           |                          |
| Slegtenhors<br>t <sup>{441}</sup><br>Slegtenhors<br>t, B.R.<br>2013}} | 66     | RYGB      | 66       | 12               | 13        | 3         |                          | 19           | 4         |                          |           |                          |

|                                     |     |         |     |    |    |   |    |    |    |    |    |    |
|-------------------------------------|-----|---------|-----|----|----|---|----|----|----|----|----|----|
| Yazbek{{43<br>9 Yazbek,T.<br>2013}} | 90  | SG      | 90  | 24 | 14 | 9 |    | 32 | 17 |    | 17 | 14 |
| Yeung{{411<br>Yeung,L.<br>2015}}    | 104 | RYGB/SG | 104 |    | 17 | 5 | 14 | 50 | 14 | 28 |    |    |

## Figures

Figure 1: PRISMA flow diagram.{{239 Moher,D. 2010}}






Figure 2: Meta-analysis of studies comparing %EWL between B-RYGB and B-SG at 6, 12 and 24 months.


a) 6 months



b) 12 months



c) 24 months



## **Appendix 1: Electronic Search Strategy**

A comprehensive literature search was run Medline, Embase, The Cochrane Library and NHS Evidence up to November 2015. The following search strategy was used:

‘Laparoscopic Adjustable Gastric Banding OR Laparoscopic Sleeve Gastrectomy OR Laparoscopic Roux-en-Y Gastric Bypass’, ‘Revision OR Revisional OR Reoperation OR Salvage OR Rescue OR Repeat’, ‘Weight loss OR Postoperative Complication OR Surgical Complication OR Morbidity OR Mortality OR Quality of Life OR Comorbidities’.